Lipid Regulators Market Size, Share & Global Analysis - 2032

Lipid Regulators Market – By Type (Statins [Branded, Combination], Non-statins [Fibric-acid Derivatives, Bile-acid]), By Indication (Hypercholesterolemia, Coronary Artery Disease), By Route of Administration, Distribution Channel & Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Data collection

1.4&nbsp;&nbsp;&nbsp; Forecast parameters

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp; Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp; Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of cardiovascular diseases

3.2.1.2&nbsp;&nbsp;&nbsp; Advancements in drug development

3.2.1.3&nbsp;&nbsp;&nbsp; Growing geriatric population

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Side effects associated with lipid regulators

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.5.1&nbsp;&nbsp;&nbsp; Supplier power

3.5.2&nbsp;&nbsp;&nbsp; Buyer power

3.5.3&nbsp;&nbsp;&nbsp; Threat of new entrants

3.5.4&nbsp;&nbsp;&nbsp; Threat of substitutes

3.5.5&nbsp;&nbsp;&nbsp; Industry rivalry

3.6&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Statins

5.2.1&nbsp;&nbsp;&nbsp; Branded statins

5.2.2&nbsp;&nbsp;&nbsp; Statin combination

5.2.3&nbsp;&nbsp;&nbsp; Generic statins

5.3&nbsp;&nbsp;&nbsp; Non-statins

5.3.1&nbsp;&nbsp;&nbsp; Fibric-acid derivatives

5.3.2&nbsp;&nbsp;&nbsp; Bile-acid sequestrants

5.3.3&nbsp;&nbsp;&nbsp; Ezetimibe

5.3.4&nbsp;&nbsp;&nbsp; Nicotinic acid derivatives

5.3.5&nbsp;&nbsp;&nbsp; PCSK9 inhibitors

5.3.6&nbsp;&nbsp;&nbsp; Other non-statins

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Hypercholesterolemia

6.3&nbsp;&nbsp;&nbsp;Hypertriglyceridemia

6.4&nbsp;&nbsp;&nbsp;Coronary artery disease

6.5&nbsp;&nbsp;&nbsp; Other indications

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Oral

7.3&nbsp;&nbsp;&nbsp; Injectable

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

8.3&nbsp;&nbsp;&nbsp; Retail pharmacies

8.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; AbbVie Inc

10.2&nbsp;&nbsp;&nbsp; Amgen Inc.

10.3&nbsp;&nbsp;&nbsp; AstraZeneca plc

10.4&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb

10.5&nbsp;&nbsp;&nbsp; Dr. Reddy&#39;s Laboratories Ltd.

10.6&nbsp;&nbsp;&nbsp; Merck &amp; Co.

10.7&nbsp;&nbsp;&nbsp; Novartis AG

10.8&nbsp;&nbsp;&nbsp; Pfizer, Inc.

10.9&nbsp;&nbsp;&nbsp; Sanofi

10.10&nbsp;&nbsp;&nbsp; Teva Pharmaceuticals 
&nbsp;

Lipid Regulators Market

Get a free sample of this report